Autism causes incapacitating neurologic problems in children that last a lifetime. The author of this article previously hypothesized that autism may be caused by autoimmunity to the brain, possibly triggered by a viral infection. This article is a summary of laboratory findings to date plus new data in support of an autoimmune pathogenesis for autism.
Methods
Autoimmune markers were analyzed in the sera of autistic and normal children, but the cerebrospinal fluid (CSF) of some autistic children was also analyzed. Laboratory procedures included enzyme-linked immunosorbent assay and protein immunoblotting assay.
Results
Autoimmunity was demonstrated by the presence of brain autoantibodies, abnormal viral serology, brain and viral antibodies in CSF, a positive correlation between brain autoantibodies and viral serology, elevated levels of proinflammatory cytokines and acute-phase reactants, and a positive response to immunotherapy. Many autistic children harbored brain myelin basic protein autoantibodies and elevated levels of antibodies to measles virus and measles-mumps-rubella (MMR) vaccine. Measles might be etiologically linked to autism because measles and MMR antibodies (a viral marker) correlated positively to brain autoantibodies (an autoimmune marker)—salient features that characterize autoimmune pathology in autism. Autistic children also showed elevated levels of acute-phase reactants—a marker of systemic inflammation.
Conclusions
The scientific evidence is quite credible for our autoimmune hypothesis, leading to the identification of autoimmune autistic disorder (AAD) as a major subset of autism. AAD can be identified by immune tests to determine immune problems before administering immunotherapy. The author has advanced a speculative neuroautoimmune (NAI) model for autism, in which virus-induced autoimmunity is a key player. The latter should be targeted by immunotherapy to help children with autism.
SinghVK.Immunotherapy for brain disease and mental illnesses. Progress in Drug Research. 1991;48:129–146.
2.
SinghVK. Neuro-immunopathogenesis in autism. In: BercziI, ReginaldM, GorczynskiRM, eds. New foundation of biology. Amsterdam: Elsevier BV Press;2001:443–454.
3.
SinghVK.Cytokine regulation in autism. In: KronfolZ, ed. Cytokines and mental health.Boston, MA: Kluwer Academic Publishers;2003:369–383.
4.
SinghVK.Rehabilitation of autism by immune modulation therapy. Journal of Special Education and Rehabilitation. 2004;3–4:161–178.
5.
BertrandJ, MarsA, BoyleC, . Prevalence of autism in a United States population: the Brick Township, New Jersey, investigation. Pediatrics. 2001;108:1155–1161.
6.
YazbakFE.Autism in the United States: a perspective. Journal of American Physicians and Surgeons. 2003;8:103107.
7.
TrottierG, SrivastavaL, WalkerCD.Etiology and infantile autism: a review of recent advances in genetic and neurobiological research. Psychiatry J. Neurosci.1999;24:95–96.
8.
SinghVK, FudenbergHH, EmersonD, . Immunodiagnosis and immunotherapy in autistic children. Ann N Acad Y. Sci.1988;540:602–604.
9.
SinghVK, WarrenRP, OdellJD, . Changes of soluble interleukin-2, interleukin-2-receptor, T8 antigen, and interleukin-1 in the serum of autistic children. Clin Immunol Immunopathol. 1991;61:448–455.
10.
SinghVK, WarrenRP, OdellJD, . Antibodies to myelin basic protein in children with autistic disorder. Brain Behav Immun. 1993;7:97–103.
11.
ComiAM, ZimmermanAW, FryeV, . Familial clustering of autoimmune disorders and evaluation of medical risk factors in autism. J Child Neurol. 1999;14:388–394.
12.
MouridsenSE, RichB, IsagerT, . Autoimmune diseases in parents of children with infantile autism: a casecontrol study. Dev Med Child Neurol. 2007;49:429–432.
13.
SinghVK.Brain autoimmunity in autism. Presented at: Annual Conference of Long Beach Chapter for Autism Society of America; October 13-14, 1996; Long Beach, CA, USA.
14.
NeumannH, CavalieA, JenneDE, . Induction of MHC class I in neurons. Science. 1995;269:549–552.
15.
KukleyM, CapetilloZ, DietrichD.Vesicular glutamate release from axons in white matter. Nature Neuroscience. 2007;10:311–320.
16.
ZiskinJL, NishiyamaA, RubioM, . Vesicular release of glutamate from unmyelinated axons in white matter. Nature Neurosci. 2007;10:321–330.
17.
SinghVK, RivasWH.Prevalence of serum antibodies to caudate nucleus in autistic children. Neuroscience Lett. 2004;355:53–64.
18.
SinghVK, WarrenRP, AverettR, . Circulating autoantibodies to neuronal and glial filament proteins in autism. Pediatric Neurol. 1997;16:88–90.
19.
SinghVK, SinghEA, WarrenRP.Hyperserotoninemia and serotonin receptor antibodies in children with autism but not mental retardation. Biol Psychiatry. 1997;41:753–755.
20.
SinghVK.Elevation of serum C-reactive protein and S100 proteins for systemic inflammation in autistic children. Journal of Special Education and Rehabilitation. 2005;3–4:117-125.
21.
SinghVK, LinSY, YangVC.Serological association of measles virus and human herpesvirus-6 with brain autoantibodies in autism. Clin Immunol Immunopathol. 1998;89:105–108.
22.
SinghVK, LinXE, NewellE, . Abnormal measlesmumps-rubella antibodies and CNS autoimmunity in children with autism. J Biomed Sci. 2002;461:359–364.
23.
SinghVK, JensenR.Elevated levels of measles antibodies in children with autism. Pediatr Neurol. 2003;28:292–294.
24.
SinghVK.Autism, vaccines, and immune reactions. Presented at: Institute of Medicine (IOM) Conference, National Academy of Sciences, February 9, 2004; Washington, DC, USA.
25.
CroonenberghsJ, BosmansE, DebouttteD, . Activation of the inflammatory response system in autism. Neuropsychology. 2002;45:1–6.
26.
VargasDL, NascimbeneC, KrishnanC, . Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol. 2005;57:67–81.
27.
HerbertMR, ZieglerDA, NormandinJJ, . White matter in autism and developmental language disorder: localization of volumetric increase with a novel parcellation method. Presented at: Annual Meeting of the Society for Neuroscience (SfN); November 8-12, 2003; New Orleans LA, USA.
28.
HerbertMR.Autism: a brain disorder, or a disorder that affects the brain. Clinical Neuropsychiatry. 2005;2:354–379.
29.
ChessS, FernandezP, KornS.Behavioral consequences of congenital rubella. J Pediatr. 1978;93:699–703.
30.
IvarssonSA, BjerraL, VegforsP, . Autism as one of several disabilities in two children with congenital cytomegalovirus infection. Neuropediatrics. 1989;21:102–103.
31.
WarrenRP, SinghVK, AverettRE, . Immunogenetic studies in autism and related disorders. Mol Chem Neuropathol. 1996;28:77–81.
32.
GuptaS, AggarwalS, HeadsC.Dysregulated immune system in children with autism: beneficial effects of intravenous immune globulin on autistic characteristics. J Autism Dev Disord. 1996;26:439–452.
33.
WarrenRP, FosterA, MargarettenNC, . Immune abnormalities in patients with autism. J Autism Dev Disord. 1986;16:189–197.
34.
WarrenRP, FosterA, MargarettenNC.Reduced natural killer cell activity in autism. J Am Acad Child Adolesc Psychiatry. 1987;26:333–335.
35.
PlioplysAV, GreavesA, KazemiK, . Lymphocyte function in autism and Rett syndrome. Neuropsychobiology. 1994;29:12–16.
36.
YonkLJ, WarrenRP, BurgerRA, . CD4+ helper T cell depression in autism. Immunol Lett. 1990;25:341–346.
37.
MenageP, ThibaultG, BarthelemyC, . CD4+ CD45RA+ T lymphocyte deficiency in autistic children: effect of a pyridoxine-magnesium treatment. Brain Dysfunction. 1992;5:326–333.
38.
SinghVK.Plasma increase of interleukin-12 and interferon-gamma: pathological significance in autism. Neuroimmunol J.1996;66:143–145.
39.
FudenbergHH.Dialyzable lymphocyte extract (DlyE) in infantile onset autism: a pilot study. Biotherapy. 1996;9:143–147.
40.
BradstreetJ, SinghVK, El-DahrJ.High-dose intravenous immunoglobulin improves symptoms in children with autism. Presented at: 55th Annual Meeting of the American Allergy, Asthma and Immunology (AAAI); July 13-18, 1991; Boston MA, USA.
41.
SinghVK.Neuroautoimmunity and immune therapy in autism. Annals of Neurosciences. 2007;14:(suppl)54–55.
42.
SinghVK, RivasWH.Detection of antinuclear and antilaminin antibodies in autistic children who received thimerosal-containing vaccines. J Biomed Sci2004;11:607–610.
43.
SinghVK, HansonJ.Assessment of metallothionein and antibodies to metallothionein in normal and autistic children having exposure to vaccine-derived thimerosal. Pediatr Allergy Immunol. 2006;17:291–296.
44.
UhlmannV, MartinCM, ScheilsO, . Potential viral pathogenic mechanism for a new variant inflammatory bowel disease. J Clin Pathol. 2002;55:84–90.
45.
WakefieldAJ, StottC, LambK.Gastrointestinal comorbidity, autistic regression and measles-containing vaccines, positive, re-challenge and biological gradient. Medical Veritas. 2006;3:796–802.
46.
EricksonCA, StiglerKA, CorkinsMR, . Gastrointestinal factors in autistic disorder: a critical review. J Aut Develop Disord. 2005;35:713–727.
47.
MudurG.Indian scientists warn of “mutant measles” virus. BMJ. 2001;322:693.
48.
BernardS, EnayatiA, RedwoodL, . Autism: a novel form of mercury poisoning. Med Hypotheses. 2001;56:462–471.
49.
NelsonKB, BaumanM.Thimerosal and autism? Pediatrics. 2003;111:674–679.
50.
BernardA, Fevre-MontangeM, BencsikA, . Brain structures selectively targeted by canine distemper mouse in a mouse model infection. Neuropathol J. Exp Neurol.1993;52:471–480.
51.
HrdickaM.Structural neuroimaging in autism. Neuro Endocrinol Lett. 2008;29:281–286.
52.
TishonA, ManchesterM, ScheiflingerF, . A model of measles virus-induced immunosuppression: enhanced susceptibility of neonatal human PBLs. Nat Med. 1996;2:1250–1254.
53.
OvsyannikovaIG, DhimanN, JacobsonRM, . Frequency of measles virus-specific CD4+ and CD8+ T cells in subjects seronegative or highly seropositive for measles vaccine. Clin Diagn Lab Immunol. 2003;10:411–416.
54.
PabstHF, SpadyDW, CarsonMM, . Kinetics of immunologic responses after primary MMR vaccination. Vaccine. 1997;15:10–14.
55.
DhimanN, OvsyannikovaIG, RyanJE, . Correlations among measles virus-specific antibody, lymphoproliferation and Th1/Th2 cytokine responses following measles-mumps-rubella-II (MMR-II) vaccination. Clin Exp Immunol. 2005;142:498–504.
56.
GriffinDE, WardBJ, JaureguiE, . Immune activation in measles. NEJM. 1989;320:1667–1672.
57.
HusseyGD, KleinM.A randomized, controlled trial of vitamin A in children with severe measles. NEJM. 1990;323:160–164.
58.
WHO and UNICEF Committee on Infectious Diseases. VitaminAtreatment of measles. Pediatrics. 1993;91:1014–1015.
59.
MegsonMN.Is autism a G-alpha protein defect reversible with vitamin A? Med Hypotheses. 2000;54:979–983.
60.
TrinchieriG.Interleukin-12 and its role in the generation of TH1 cells. Immunol Today. 1993;14:335–338.
61.
LiblauRS, SingerSM, McDevittHO.Th1 and Th2 CD4+ cells in the pathogenesis of organ-specific diseases. Immunol Today. 1995;16:34–38.
62.
SzalaiAJ.C-reactive protein (CRP) and autoimmune disease: facts and conjectures. Clin Dev Immunol. 2004;11:221–226.
63.
GutmannJ: GSH: your body's most powerful protector, glutathione. Montreal: Communications Kuda. ca Inc.; 2002.
64.
BuitelaarJK, Van EngelandH, de KogelKH, . The adrenocorticotrophic hormone (4-9) analog ORG 2766 benefits autistic children: report on a second controlled clinical trial. J Am Acad Child Adolesc Psychiatry. 1992;31:1149–1156.
65.
KeeganM, PinedaAA, McClellandRL, . Plasma exchange for severe attacks of CNS dysmyelination: predictors of response. Neurology. 2002;58:143–146.
66.
SinghVK.Autoimmunity in brain disorders and mental illnesses. In: RogersSJ, ed. Tics and Tourette's: breakthrough discoveries in natural treatments. Royal Palm Beach, FL, USA: Association for Comprehensive Neuro Therapy;2005:163–168.
67.
SinghVK.Autoimmune pathogenesis of autism: profiling an autoimmune subset. Invited presentation at: Third International Medical Convention—Autism Medical Conference, sponsored by Autisme et troubles envahissants du developpement Montreal (ATEDM); May 3-4, 2002; Montreal, Quebec, Canada.
